|
Consent collection
|
x
| | | | | | | | | | | | | |
|
Pursuit consent collection
| |
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
| |
|
Demographics, medical history, disease characteristics
|
x
| | | | | | | | | | | | | |
|
Administration of IVIG or placebo therapy
| |
x
|
x
|
x
|
x
| | | | | | | | | |
|
Main outcome measurement
| |
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
| |
|
Collection of clinical data
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
| |
|
Complete blood count, blood gas, creatinine
|
x
|
x
| | | | | |
x
|
x
| |
x
| |
x
| |
|
Leukocytosis, C-reactive protein, biobank collection
|
x
|
x
| | | | | |
x
| | |
x
| | | |
|
SOFA score
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
| |
|
Adverse events
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
Final assessment of main outcome
| | | | | | | | | | | | |
x
| |
|
Final assessment of secondary outcomes
| | | | | | | | | | | | |
x
|
x
|
